|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Blood infection due to Candida species are major cause of morbidity and mortality in hospitalised patients. The spectrum of candidemia has changed to Non albicans Candida species and also shows resistance to commonly used azoles drugs. To study prevalence of Candida species isolated from blood culture samples and to isolate and identify different Candida species with their antifungal susceptibility testing. Blood samples were collected and incubated in automated blood culture system. Candida species was isolated by culture on sabouraud dextrose agar and species identification done by standard biochemical reactions. Antifungal susceptibility testing done by disc diffusion method as per CLSI guidelines. Out of total 6455 blood samples 1399 (21.67%) samples are positive for growth. Pure growth of Candida species was seen in 100(7.14%) positive blood samples. Among total 100 isolates, 41(41%) was Candida albicans followed by Candida glabrata 25(25%), Candida tropicalis 23(23%), Candida krusei 5(5%), Candida parapsilosis 5(5%) and Candida gullermondii 1(1%). Antifungals drug like fluconazole shows 25% resistance, Voriconazole 23% resistance, Itraconazole 36% resistance and Miconazole 20% resistance among different Candida species. Antifungal susceptibility shows lower resistant (3%) to amphotericin B, where high incidence of azole resistance among Non albicans Candida species. Species-level identification of Candida and their antifungal sensitivity testing should to be performed to achieve better clinical result and to select an appropriate and effective antifungal therapy. High resistance to antifungal agents is an alarming sign to the healthcare professionals.